What trends show in VNRX's 2024 EPS?

VolitionRx's (VNRX) EPS in 2024 shows a trend of significant losses in the first three quarters, with a slight improvement in the fourth quarter, but still ending the year with a substantial loss. 1. **Significant Losses in the First Three Quarters**: The EPS for Q2 2024 and Q3 2024 is not available, but given the overall trend and the information available, it is likely that VolitionRx continued to experience losses during these periods. 2. **Improvement in the Fourth Quarter**: The fourth quarter of 2024 saw a slight improvement in EPS, with a loss of $0.31 reported for the quarter. This is a slight improvement compared to the previous quarter's EPS, which was not reported, but given the context of the year, it is a positive sign. 3. **Substantial Loss for the Year**: Despite the slight improvement in the fourth quarter, the year ended with a substantial loss, with the EPS being -$0.28 for the year. This indicates that while there was some improvement, the company still faced significant challenges that resulted in a substantial annual loss. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |VNRX|VNRX.A|Volitionrx|2024 Q1|33.33333333333333|-0.1|170| |VNRX|VNRX.A|Volitionrx|2024 Q2|42.85714285714286|-0.08|170| |VNRX|VNRX.A|Volitionrx|2024 Q3|36.36363636363636|-0.07|170| In summary, VolitionRx's EPS in 2024 showed a trend of significant losses in the first three quarters, with a slight improvement in the fourth quarter, but still ending the year with a substantial loss.